NFE2L3 and neoplasm: However, knockdown of NFE2L3 enhanced the efficacy of lymphocyte-mediated tumor killing in the Kearney 2018 NK_10, Pech 2019 NK_E/T = 1, and Shifrut 2018 average cohorts (Figure 8D).